CD4 levels and NSCLC metastasis: the benefits of maintaining moderate levels.
Bai Y, Liu Y, Wu J, Miao R, Xu Z, Hu C, Zhou J, Guo J, Xie J, Shi Z, Ding X, Xing Y, Hu D.
Bai Y, et al.
J Cancer Res Clin Oncol. 2023 Dec;149(18):16827-16836. doi: 10.1007/s00432-023-05418-2. Epub 2023 Sep 21.
J Cancer Res Clin Oncol. 2023.
PMID: 37733240